The U.S. FDA’s accelerated approval of Vanrafia (atrasentan) from Novartis AG for primary immunoglobulin A nephropathy (IgAN) is the company’s second approval for the indication in the past year and a half. The nod also came without a required safety program through a black box warning.
Ushering in a new class of antibiotics, the U.S. FDA approved GSK plc’s gepotidacin for use in uncomplicated urinary tract infections. Branded Blujepa, the oral triazaacenaphthylene bacterial topoisomerase inhibitor is indicated for treating female adults and adolescents, 12 and older.
Retinoic acid receptor alpha (RARα) is a nuclear receptor with a central role in spermatogenesis. Genetic knockout studies in mice have shown that the lack of RARα leads to a complete absence of sperm production without affecting overall health, suggesting that targeted inhibition of RARα may constitute a feasible strategy for male contraception.